The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Recent Advances in Chemoprevention of Cancer
Abstract
Chemoprevention is the use of pharmacologic or natural agents that inhibit the development of invasive cancer either by blocking the DNA damage that initiates carcinogenesis or by arresting or reversing the progression of premalignant cells in which such damage has already occurred. Recent advances in our understanding of the mechanisms of carcinogenesis have led to the synthesis of new drugs that can inhibit tumor development in experimental animals by selective action on specific molecular targets, such as the estrogen, androgen, and retinoid receptors or inducible cyclooxygenase. Several of these agents (including tamoxifen, 13- cis -retinoic acid, retinyl palmitate, and an acyclic retinoid) are clinically effective in preventing the development of cancer, particularly in patients who are at high risk for developing second primary tumors after surgical removal of the initial tumor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Cloning of a novel receptor expressed in rat prostate and ovary.
Kuiper, G. G., Enmark, E., Pelto-Huikko, M., Nilsson, S., & Gustafsson, J. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5925 · Cited by 4,788
Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Häggblad, J., Nilsson, S., & Gustafsson, J.-A. (1997) · Endocrinology · doi:10.1210/endo.138.3.4979 · Cited by 4,442
Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717
Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. P., Kramer, A. M., Lotan, R., Peters, L. J., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199009203231205 · Cited by 1,365
Self-citation13-cis-Retinoic Acid in the Treatment of Oral Leukoplakia
Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., et al. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612113152401 · Cited by 819
Self-citationSulindac causes regression of rectal polyps in familial adenomatous polyposis
Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., & Attali, P. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90519-q · Cited by 719
Muto, Y., Moriwaki, H., Ninomiya, M., Adachi, S., Saito, A., Takasaki, K. T., Tanaka, T., Tsurumi, K., Okuno, M., Tomita, E., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199606133342402 · Cited by 668
Black, L. J., Sato, M., Rowley, E. R., Magee, D. E., Bekele, A., Williams, D. C., Cullinan, G. J., Bendele, R., Kauffman, R. F., & Bensch, W. R. (1994) · Journal of Clinical Investigation · doi:10.1172/jci116985 · Cited by 609
Cited by
Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium
Olumi, A., Grossfeld, G., Hayward, S., Carroll, P., Cunha, G., Hein, P., & Tlsty, T. (2000) · Breast Cancer Research · doi:10.1186/bcr138 · Cited by 1,463
Thun, M. J., Henley, S. J., & Patrono, C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.4.252 · Cited by 1,433
Delgado-Vargas, F., Jiménez, A. R., & Paredes-López, O. (2000) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408690091189257 · Cited by 1,421
Principles for modulation of the nuclear receptor superfamily
Gronemeyer, H., Gustafsson, J.-Å., & Laudet, V. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1551 · Cited by 1,226
Diefenbach, A., Jamieson, A. M., Liu, S. D., Shastri, N., & Raulet, D. H. (2000) · Nature Immunology · doi:10.1038/77793 · Cited by 878
“and it could be speculated that induction of NKG2D ligands may in some cases contribute to the well documented chemotherapeutic activities of retinoic aci”
BackgroundManna, S. K., Mukhopadhyay, A., & Aggarwal, B. B. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6509 · Cited by 879
The Role of Resveratrol in Cancer Therapy
Ko, J.-H., Sethi, G., Um, J.-Y., Shanmugam, M. K., Arfuso, F., Kumar, A. P., Bishayee, A., & Ahn, K. S. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122589 · Cited by 800
Cragg, G. M., & Pezzuto, J. M. (2016) · Medical Principles and Practice · doi:10.1159/000443404 · Cited by 798
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part I)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.20.1529 · Cited by 757
Myofibroblasts. II. Intestinal subepithelial myofibroblasts
Powell, D. W., Mifflin, R. C., Valentich, J. D., Crowe, S. E., Saada, J. I., & West, A. B. (1999) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1999.277.2.c183 · Cited by 566
Apoptosis as a Novel Target for Cancer Chemoprevention
Sun, S.-Y., Hail, N., & Lotan, R. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh123 · Cited by 502
Combinatorial chemoprevention of intestinal neoplasia
Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, K. W., Vogelstein, B., Wissner, A., Nunes, M., Frost, P., & Discafani, C. M. (2000) · Nature Medicine · doi:10.1038/79534 · Cited by 493
Sporn, M. B., & Suh, N. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.525 · Cited by 439
Self-citationVeronesi, U., De Palo, G., Marubini, E., Costa, A., Formelli, F., Mariani, L., Decensi, A., Camerini, T., Del Turco, M. R., Di Mauro, M. G., et al. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.21.1847 · Cited by 419
Self-citationPomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer
Malik, A., Afaq, F., Sarfaraz, S., Adhami, V. M., Syed, D. N., & Mukhtar, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505870102 · Cited by 401
Cyclooxygenase-2 Inhibitors in Tumorigenesis (Part II)
Taketo, M. M. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.21.1609 · Cited by 399
Cancer Chemopreventive Activity of Resveratrol
BHAT, K. P. L., & PEZZUTO, J. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb02918.x · Cited by 398
International Union of Pharmacology. LX. Retinoic Acid Receptors
Germain, P., Chambon, P., Eichele, G., Evans, R. M., Lazar, M. A., Leid, M., De Lera, A. R., Lotan, R., Mangelsdorf, D. J., & Gronemeyer, H. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.4 · Cited by 397
Oral Cavity and Esophageal Carcinogenesis Modeled in Carcinogen-Treated Mice
Tang, X.-H., Knudsen, B., Bemis, D., Tickoo, S., & Gudas, L. J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0999-3 · Cited by 390
Natural Products/Bioactive Compounds as a Source of Anticancer Drugs
Asma, S. T., Acaroz, U., Imre, K., Morar, A., Shah, S. R. A., Hussain, S. Z., Arslan-Acaroz, D., Demirbas, H., Hajrulai-Musliu, Z., Istanbullugil, F. R., et al. (2022) · Cancers · doi:10.3390/cancers14246203 · Cited by 378
Genetic progression in the pancreatic ducts
Hruban, R. H., Wilentz, R. E., & Kern, S. E. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65054-7 · Cited by 373
Retinoid pathway and cancer therapeutics
Bushue, N., & Wan, Y.-J. Y. (2010) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.07.003 · Cited by 373
Almatroodi, S. A., Almatroudi, A., Khan, A. A., Alhumaydhi, F. A., Alsahli, M. A., & Rahmani, A. H. (2020) · Molecules · doi:10.3390/molecules25143146 · Cited by 365
Mao, L., Hong, W. K., & Papadimitrakopoulou, V. A. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00090-x · Cited by 365
Self-citationHsieh, T.-C., & Wu, J. M. (1999) · Experimental Cell Research · doi:10.1006/excr.1999.4471 · Cited by 361
Ka, H., Park, H.-J., Jung, H.-J., Choi, J.-W., Cho, K.-S., Ha, J., & Lee, K.-T. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00238-6 · Cited by 360
Mantena, S. K., Sharma, S. D., & Katiyar, S. K. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0448 · Cited by 353
Altucci, L., Rossin, A., Raffelsberger, W., Reitmair, A., Chomienne, C., & Gronemeyer, H. (2001) · Nature Medicine · doi:10.1038/89050 · Cited by 340
Zhao, J., Wang, J., Chen, Y., & Agarwal, R. (1999) · Carcinogenesis · doi:10.1093/carcin/20.9.1737 · Cited by 328
Cancer and Inflammation: Promise for Biologic Therapy
Demaria, S., Pikarsky, E., Karin, M., Coussens, L. M., Chen, Y.-C., El-Omar, E. M., Trinchieri, G., Dubinett, S. M., Mao, J. T., Szabo, E., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181d32e74 · Cited by 325
‘Angioprevention’: angiogenesis is a common and key target for cancer chemopreventive agents
Tosetti, F., Ferrari, N., De Flora, S., & Albini, A. (2002) · The FASEB Journal · doi:10.1096/fj.01-0300rev · Cited by 324
Lippman, S. M., Lee, J. J., Karp, D. D., Vokes, E. E., Benner, S. E., Goodman, G. E., Khuri, F. R., Marks, R., Winn, R. J., Fry, W., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.8.605 · Cited by 321
Self-citationHuman, Rat, and Mouse Metabolism of Resveratrol
Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G., & van Breemen, R. B. (2002) · Pharmaceutical Research · doi:10.1023/a:1021414129280 · Cited by 319
Perspectives on Cancer Chemoprevention Research and Drug Development
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)61026-x · Cited by 317
Retinoids in cancer therapy and chemoprevention: Promise meets resistance
Freemantle, S. J., Spinella, M. J., & Dmitrovsky, E. (2003) · Oncogene · doi:10.1038/sj.onc.1206936 · Cited by 312
Chemoprevention through the Keap1–Nrf2 signaling pathway by phase 2 enzyme inducers
Kwak, M.-K., Wakabayashi, N., & Kensler, T. W. (2004) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.06.041 · Cited by 311
Targeting NRF2 signaling for cancer chemoprevention
Kwak, M.-K., & Kensler, T. W. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.08.028 · Cited by 305
Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights
De Sá Coutinho, D., Pacheco, M. T., Frozza, R. L., & Bernardi, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061812 · Cited by 290
Fukumoto, S.-I., Yamauchi, N., Moriguchi, H., Hippo, Y., Watanabe, A., Shibahara, J., Taniguchi, H., Ishikawa, S., Ito, H., Yamamoto, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1238 · Cited by 289
Chemoprevention by isothiocyanates and their underlying molecular signaling mechanisms
Keum, Y.-S., Jeong, W.-S., & Tony Kong, A. N. (2004) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2004.05.024 · Cited by 282
Aspirin, salicylates, and cancer
Elwood, P. C., Gallagher, A. M., Duthie, G. G., Mur, L. A., & Morgan, G. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60243-9 · Cited by 282
Agarwal, R. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00385-3 · Cited by 280
Cancer Risk and Low-Penetrance Susceptibility Genes in Gene-Environment Interactions
Shields, P. G., & Harris, C. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.11.2309 · Cited by 275
Retinoids in chemoprevention and differentiation therapy
Hansen, L. A., Sigman, C. C., Andreola, F., Ross, S. A., Kelloff, G. J., & Luca, L. M. D. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.271 · Cited by 270
Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1104 · Cited by 270
Self-citationPrevention of Second Primary Tumors by an Acyclic Retinoid in Patients with Hepatocellular Carcinoma
Muto, Y., Moriwaki, H., & Saito, A. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904013401315 · Cited by 265
Hop ( Humulus lupulus )-Derived Bitter Acids as Multipotent Bioactive Compounds
Van Cleemput, M., Cattoor, K., De Bosscher, K., Haegeman, G., De Keukeleire, D., & Heyerick, A. (2009) · Journal of Natural Products · doi:10.1021/np800740m · Cited by 263
Biologically Active Compounds from Hops and Prospects for Their Use
Karabín, M., Hudcová, T., Jelínek, L., & Dostálek, P. (2016) · Comprehensive Reviews in Food Science and Food Safety · doi:10.1111/1541-4337.12201 · Cited by 263
Yoo, C.-B., Han, K.-T., Cho, K.-S., Ha, J., Park, H.-J., Nam, J.-H., Kil, U.-H., & Lee, K.-T. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.11.018 · Cited by 262
Functions, Therapeutic Applications, and Synthesis of Retinoids and Carotenoids
Álvarez, R., Vaz, B., Gronemeyer, H., & de Lera, Á. R. (2014) · Chemical Reviews · doi:10.1021/cr400126u · Cited by 260
Weiss, F. U., Marques, I. J., Woltering, J. M., Vlecken, D. H., Aghdassi, A., Partecke, L. I., Heidecke, C., Lerch, M. M., & Bagowski, C. P. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.08.065 · Cited by 257
Chun, K.-H., Kosmeder, J. W., Sun, S., Pezzuto, J. M., Lotan, R., Hong, W. K., & Lee, H.-Y. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.4.291 · Cited by 255
Self-citationPavlova, I., Williams, M., El-Naggar, A., Richards-Kortum, R., & Gillenwater, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1609 · Cited by 253
Kapadia, G. J., Azuine, M. A., Tokuda, H., Takasaki, M., Mukainaka, T., Konoshima, T., & Nishino, H. (2002) · Pharmacological Research · doi:10.1006/phrs.2002.0992 · Cited by 238
Spinella, M. J., Freemantle, S. J., Sekula, D., Chang, J. H., Christie, A. J., & Dmitrovsky, E. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.22013 · Cited by 165
Delivery of retinoid-based therapies to target tissues
Moise, A. R., Noy, N., Palczewski, K., & Blaner, W. S. (2007) · Biochemistry · doi:10.1021/bi7003069 · Cited by 93
Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells
Gulappa, T., Reddy, R. S., Suman, S., Nyakeriga, A. M., & Damodaran, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.05.014 · Cited by 43
PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of irinotecan
Emami, J., Maghzi, P., Hasanzadeh, F., Sadeghi, H., Mirian, M., & Rostami, M. (2018) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2017.1340950 · Cited by 36
Metadata
- Authors
- Hong, W. K., & Sporn, M. B.
- Venue
- Science
- Published
- 1997-11-07
- Volume
- 278
- Issue
- 5340
- Pages
- 1073-1077
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1978052764
- Cited by
- 827
- References
- 27
- FWCI
- 37.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.